Abstract Number: 1745 • ACR Convergence 2024
Use of Statins and Its Association with Major Adverse Cardiovascular Outcomes with Tofacitinib versus TNF Inhibitors in a Risk-Enriched Population of Patients with Rheumatoid Arthritis
Background/Purpose: ORAL Surveillance (NCT02092467; a post-authorization safety study of tofacitinib 5 and 10 mg twice daily [BID] vs TNF inhibitors [TNFi]) found higher incidence of…Abstract Number: 0250 • ACR Convergence 2024
Effectiveness of Tuberculosis Preventive Treatment in Patients with Rheumatic Diseases: A Global Meta-analysis of Cohort Studies
Background/Purpose: As patients with rheumatic diseases (RDs) growing into a large population globally, concerns continue exist regarding the potential development of tuberculosis (TB) in this…Abstract Number: 1880 • ACR Convergence 2024
Statewide Burden of Osteoarthritis in India and Its Trend from 1990-2021: A Benchmarking Analysis
Background/Purpose: Osteoarthritis (OA) imposes a significant health burden globally, with India experiencing substantial demographic and epidemiological changes over the past three decades. This study addresses…Abstract Number: 0255 • ACR Convergence 2024
“Rheum” to Improve: Have Patients Attending the Young Adult Systemic Erythematosus (YASLE) Clinic Received All Appropriate Vaccinations? A Quality Improvement Initiative
Background/Purpose: Infections are a leading cause of morbidity and mortality in patients with childhood-onset systemic lupus erythematosus (cSLE). Vaccination is a powerful tool to prevent…Abstract Number: 1884 • ACR Convergence 2024
VIVA QI: Vaccination In Vasculitis: Applying a Quality Improvement Approach
Background/Purpose: The vasculitides are rare but serious conditions that are characterized by the destructive inflammation of the blood vessels. Patients living with vasculitis are often considered…Abstract Number: 0858 • ACR Convergence 2023
Randomized, Controlled, Double-Blind Trial on the Impact of Rosuvastatin on Sublinical Markers of Atherosclerosis in Patients with ANCA-Associated Vasculitis
Background/Purpose: Despite more effective therapeutic strategies in ANCA-associated vasculitis (AAV), there is still a significant risk of morbidity and mortality, mainly due to infection, and…Abstract Number: 2132 • ACR Convergence 2023
Systematic Screening for Multimorbidities Leads to an Increased Use of Comorbidity-preventing Medications and Lower Hospitalization Rates
Background/Purpose: Systematic screening for multimorbidities has been carried out since 2014 at Montpellier University Hospital in patients with chronic inflammatory rheumatism (IRD). The aim of…Abstract Number: 0938 • ACR Convergence 2023
Deconvolution of the Molecular Signature of Very Early Diagnosis of Systemic Sclerosis (VEDOSS) and Established Disease: A Biomarker Blueprint of Scleroderma Disease Continuum
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease that affects multiple organs asynchronously, leading to highly variable fibrotic damage and consequent increased morbidity and mortality.…Abstract Number: 2283 • ACR Convergence 2023
Anti-SARS-CoV-2 Vaccination Among Patients Living with Systemic Lupus Erythematosus in Sweden: Coverage and Clinical Effectiveness
Background/Purpose: Real-world data assessing the effectiveness of the anti-SARS-CoV2 vaccination in patients living with systemic lupus erythematosus (SLE) are currently lacking. We aimed to describe…Abstract Number: 1087 • ACR Convergence 2023
Characterizing Herpes Zoster Vaccination Patterns in Rheumatoid Arthritis Patients in a Tertiary Care Clinic: A Quality Improvement Approach
Background/Purpose: Patients with rheumatoid arthritis (RA) face an increased risk of herpes zoster (HZ) infection, notably those on immunosuppressive therapy. Herpes zoster infection is associated…Abstract Number: 2285 • ACR Convergence 2023
Vaccine Uptake in Women with Systemic Lupus Erythematosus (SLE) – Study Update
Background/Purpose: Infections are a major cause of morbidity & mortality in patients with systemic lupus erythematosus (SLE), including vaccine-preventable infections. SLE patients are considered to…Abstract Number: 1089 • ACR Convergence 2023
Improving Recombinant Zoster Vaccination Rates Among Immunosuppressed Veterans in an Academic Rheumatology Clinic
Background/Purpose: Due in part to immunosuppressant medications, patients with rheumatic diseases not only carry a higher risk of herpes zoster reactivation but also worse outcomes.…Abstract Number: 2490 • ACR Convergence 2023
Safety and Efficacy of Mycophenolate Mofetil in New-onset Systemic Lupus Erythematosus with High Titer of Anti-dsDNA Antibody and Without Major Organ Involvement: A Multicenter Randomized Controlled Trial
Background/Purpose: Previous clinical trials of mycophenolate mofetil (MMF) in SLE were mainly focused on lupus nephritis (LN) (patients have been diagnosed with LN). In the…Abstract Number: 0133 • ACR Convergence 2023
COVID-19 Vaccination-related Delayed Adverse Events Among Patients with Systemic Lupus Erythematosus: Results from the COVAD Study
Background/Purpose: COVID-19 vaccines have been proven to be safe in healthy populations. However, data on delayed adverse effects (AEs) in people with autoimmune diseases (AIDs),…Abstract Number: 1097 • ACR Convergence 2023
Improving Vaccine Uptake of the Pneumococcal 20-valent Conjugate Vaccine (PCV20) in Young Rheumatic Disease Patients Using a Brief Intense Partnership Program
Background/Purpose: Patients with inflammatory rheumatic diseases (IRDs) are at increased risk of infection. The Centers for Disease Control and Prevention (CDC) and the ACR strongly…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 12
- Next Page »